Review

Immune mechanisms induced by sublingual immunotherapy in allergic respiratory diseases

Umut Gazi1,2* and Nerin Nadir Bahceciler2,3,4,5

1Department of Medical Microbiology and Clinical Microbiology, Faculty of Medicine, Near East University, Nicosia, Cyprus
2Department of Pediatrics, Division of Allergy and Immunology, Faculty of Medicine, Near East University, Nicosia, Cyprus
*Correspondence: Nerin Nadir Bahceciler, Department of Pediatrics, Division of Allergy and Immunology, Faculty of Medicine, Near East University, Nicosia, Cyprus. Email: nerin74@gmail.com

Summary

Allergic respiratory diseases (ARDs) are still a major burden on global public health. Sublingual immunotherapy (SLIT) is a mode of allergen immunotherapy (AIT) which involves administration of the allergen under the tongue, and benefits from tolerogenic properties of the oral mucosa. Studies revealed reduced levels of eosinophilia and eosinophil-dominated inflammation in airways of both animals and humans after SLIT. SLIT was also suggested to lower basophil responsiveness and innate lymphoid cell-2 function in blood samples collected from patients with ARD. Moreover, apart from shifting pathogenic type 2 (T_{h2}) to a type 1 (T_{h1}) and protective regulatory (Treg) polarization of helper T-cell immune response, antibody isotype switch from IgE to IgG1, IgG2, IgG4 and IgA was also reported in patients with ARD receiving SLIT. Today, the literature on SLIT-mediated activities is still scarce and more studies are required to further enlighten the mechanisms utilized by SLIT for the induction of tolerance. The aim of this review is to summarize the current knowledge about the immune-regulatory mechanisms induced by SLIT against ARDs.

Keywords: SLIT, allergic respiratory diseases, adaptive, innate, immune response

Introduction

Today allergic respiratory diseases (ARDs) continue to be a significant global public health problem [1–3]. However, albeit humans are continuously in contact with allergens, not everyone develops allergic reaction which highlights the importance of both extrinsic as well as intrinsic factors for the inception of the disease. Numerous genetic studies correlated the risk of developing allergies with multiple genes many of which were immunity related [4, 5]. Moreover, according to the hygiene hypothesis, the elevated prevalence of allergic diseases is due to increased sterile hygiene practices in the modern world leading to dysregulation of immune system and microbiome dysbiosis because of diminished exposure to immune-stimulating microbial agents in the early childhood [6].

The AIT differs from the other pharmacological approaches for ARDs (e.g. anti-histamines, non-steroidal anti-inflammatory drugs-NSAIDs) as it can both provide protection against the symptoms and improve the natural course of the allergy. The effects are mediated by its distinctive ability to modulate the allergen-specific T-helper type 2 (T_{h2}) immune responses and induce the generation of tolerance against the causative agent by inducing immunosuppressive cytokine secretion and antigen-specific regulatory T-cell (T_{reg}) activation [7].

The AIT has subtypes that differ in the routes of allergen administration. Among those subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the two main forms of AIT that are practiced by the clinicians against ARDs [8, 9]. The SLIT is considered to be a convenient alternative to SCIT which requires frequent injections and periodic visits to medical centers, as it involves self-administration of the allergen under the tongue [10]. The SLIT is also regarded as a safer approach as it is associated with lower risk of severe systemic reactions [10]. This review summarizes the current literature on the mechanisms of action induced by SLIT against ARDs.

Immunopathogenesis of ARDs: an overview

Respiratory epithelium provides an effective barrier against invading foreign particles including microbial agents and allergens, through its physical barrier function (i.e. epithelial tight junctions), innate immune defence function (i.e. foreign particle detection and cytokine release) and mucociliary activities [11]. Various environmental factors including smoking, detergents, ozone, diesel exhaust as well as some allergens with protease enzymatic activity are known to disrupt the epithelial barrier function and tight junctions (TJs) [12]. Entry of foreign substances into the body due to disruption of the epithelial barrier initiates protective innate immune response by activating myeloid and dendritic cells (DCs), which in turn leads to generation of adaptive immune response by antigen presentation to helper T cells and cytokine release [13].
The DCs play an important role in allergic responses by presenting the internalized allergens/antigens to naïve T cells during ARDs [14]. Following the engulfment of the foreign particles, DCs display CCR7- and CCR8-dependent migration to neighboring lymph nodes in order to induce naïve CD4+ T-cell activation. In the presence of cytokines released by DCs (e.g. IL-4 and IL-13), activated T-cells differentiate to T H2 cells which in turn would promote IgE-mediated immune response [15]. Cytokines such as interleukin (IL)-25 and IL-33 which are released locally to initiate epithelial repair are known to increase T H2-polarizing capacity of DCs [16].

The alarmins can also promote T H2-mediated immune response via local innate lymphoid cell (ILC)-mediated activities which are regarded as innate counterparts of helper T cells (T H cells) and important sources of early innate effector cytokines [5]. Among the ILC subtypes, ILC2s are increasingly recognized as essential in the initiation and orchestration of allergic T H2 inflammation [17]. In atopic subjects, the resultant T H2-mediated immune response can result in further disruption of the epithelial barrier function by reducing TJ expression levels which would lead to exacerbation of allergy symptoms by increasing sensitization to the allergen and consequently promoting inflammatory response [18, 19].

Allergic sensitization results in the generation of predominantly T H2 cells which are responsible for the induction of allergen-specific IgE production by the follicular B-cells in the secondary lymphoid tissues; germinal centre B-cells which are activated by CD40-signaling undergo isotype switching from IgM to IgE in the presence of T H2 cytokines such as IL-4 and IL-13 [20, 21]. The secreted IgE antibodies set the stage for the effector phase of allergic reactions by occupying the high-affinity IgE receptors (FceRI) on mast cells and basophils. During the effector phase, the cross-linking of FceRI receptors upon interaction with IgE-bound allergens leads to release of granular mediators (e.g. histamine), lipid mediators (e.g. leukotrienes) and type 2 cytokines by mast cells and basophils [21, 22]. The released mediators lead to vasodilatation, increased vascular permeability, bronchoconstruction, and mucus production during the acute allergic reaction [23].

While the early signs of immediate allergic immune response are IgE-dependent, the late-phase reactions are mainly regulated by infiltrated T H2-cells which results in further activation of the immune cells in the microenvironment including basophils, MCs, eosinophils, and B cells. This leads to the second wave of type 2 cytokine (e.g. IL-4, IL-5) and mediator (e.g. leukotrienes, prostaglandins, histamine, tryptase, eosinophilic cationic protein, and peroxidases) release that can elevate IgE production and eosinophil infiltration [7]. Among the T H2-cytokines released in the microenvironment, IL-5 serves as the key mediator for eosinophil proliferation, while IL-4 and IL-13 facilitate the eosinophil recruitment by increasing expression levels of endothelial adhesion molecules (e.g. L-selectin, and very late antigen-4) [24]. Upon degranulation, eosinophils release granule-associated basic proteins, lipid mediators and reactive oxygen species which further exert epithelial cell damage and airway hyperactivity with mucus production. Moreover, eosinophils can also facilitate airway edema and bronchoconstriction indirectly through their modulating activities on other leukocytes including mast cells and T cells [25].

**SLIT on immune cell functions during ARDs**

Despite the growing number of studies on the contribution of AIT in the management of allergic diseases [26], the relevant literature on the SLIT in the context of ARDs is still scarce. The SLIT aims to induce mucosal immunity against airway allergic reactions through administration of allergen extract as drops or dissolvable tablet under the tongue [27, 28]. While the allergen can arrive in local lymph nodes as unbound via free diffusion, it can also be delivered by oral DCs which can migrate to the proximal lymph nodes for the activation of both allergen-specific T- and B-cells upon engulfment of the foreign particle [29]. Generation of allergen specific blocking antibodies and skewing allergen-specific immune response away from T H2 to type 1 T cell (T H1) and Treg cells are essential for the pro-tolerogenic adaptive immune responses [30].

**Innate immune cells**

In mice, sublingual antigens were able to pass through the epithelial cells to reach ducal APCs [31]. The DCs were crucial in the induction of tolerogenic T cells against allergic airway responses following SLIT [32]. Facilitating antigen uptake by DCs had a positive contribution to enhance the SLIT efficiency against ARDs [33, 34]. Moreover, inclusion of adjuvants such as Pam3CSK4; 1,25-dihydroxyvitamin D3 plus dexamethasone; and Lactobacillus plantarum which would skew the immune response away from T H2, increased SLIT-associated protective activities mediated by murine DCs against airway hyperresponsiveness [35, 36]. Nevertheless, there has not yet been any study on the role played by distinct DC subtypes including myeloid and Langerhans types (LCs) latter of which was shown to be at levels higher in oral mucosa of allergic subjects compared with healthy controls [37]. Moreover, oral LCs were previously reported to differ from skin counterparts in terms of constitutive expression of IgE receptor, and elevated expression levels of major histocompatibility complex class I and II molecules as well as co-stimulatory molecules [38] that suggest tissue-specific phenotype in the oral microenvironment which may influence SLIT-induced mechanisms [39]. On the other hand, oral macrophage-like cells are also thought to migrate to cervical lymph nodes and support regulatory CD4+ T-cell function in asthmatic mice following SLIT [40].

Antigen-specific IgE production is central in pathogenesis of atopic diseases, and due to the expression of high-affinity IgE receptors eosinophils, MCs and basophils are considered as essential cells in the allergic reactions responsible for ARDs. Of those, while MCs are tissue resident cells, basophils and eosinophils home to areas of allergic inflammation [41]. In a previous study by Kaminuma et al., treatment of mice sublingually with ovalbumin (OVA) diminished eosinophil infiltration to bronchoalvolar and nasal cavities after intratracheally or intranasally challenge with OVA [42]. Following SLIT with birch pollen (BP) extract, BP-sensitized mice displayed reduced lung eosinophilia [43]. Moreover, HDM-based SLIT exhibited both prophylactic and therapeutic effects in an experimental mouse model of HDM-induced eosinophil-dominated airway inflammation [44].

Similar results were also observed in human studies since significantly reduced nasal eosinophilia was reported in patients with allergic rhinitis and/or asthma following SLIT by two independent randomized controlled studies [45, 46]. Additionally, reduced fractional exhaled nitric oxide (an
index of eosinophilic airway inflammation) and nasal eosinophil cationic protein levels were reported in patients with ARD upon SLIT [47, 48]. On the other hand, while basophil responsiveness also displayed reduction following SLIT in patients with respiratory allergies to house dust mite and timothy grass [49, 50], there has not yet any report on the effect of SLIT on the allergen-specific MC level and activity in the context of ARDs.

The ILC2s represent another tissue-resident immune cell population distributed in mucosal tissues with important roles in type 2 inflammation and allergic diseases. Peripheral blood samples collected from subjects with allergic rhinitis (AR) displayed elevated levels of ILC2 which were in positive correlation with IL-13 levels and symptom scores [51, 52]. While a previous study by Shamji et al. reported SLIT-induced elevated levels of IL-33-inducible regulatory T cells which have inhibitory activity against ILC2-mediated type 2 immune responses [52], there has not been any data demonstrating the airway ILC2 frequency and/or function in patients with ARD after SLIT.

Adaptive immune cells

The SLIT was able to prevent the development of allergic reaction in sensitized animals by normalizing imbalance between T\textsubscript{H}1 and T\textsubscript{H}2 responses by exerting inhibitory reaction in sensitized animals by normalizing imbalance [43, 44, 53–55]. Moreover, modification of SLIT with inclusion of γ interferon, IFN-γ cytokine secretion, respectively [43, 44, 51, 52]. While a previous study by Shamji et al. reported SLIT-induced elevated levels of ILC2 which have inhibitory activity against ILC2-mediated type 2 immune responses [52], there has not been any data demonstrating the airway ILC2 frequency and/or function in patients with ARD after SLIT.

Table 1: comparison of head to head SLIT versus SCIT studies in terms of clinical and immunological outcome

| Author          | Study design | No of patients | Allergen | Tx duration (month) | Clinical results | Immunologic results |
|-----------------|--------------|----------------|----------|---------------------|------------------|---------------------|
| Schulten [60]   | RC           | 40             | Grass    | 15                  | NE               | IL-5 decreased with SCIT |
|                 |              |                |          |                     |                  | IL-10 increased with SCIT/SLIT |
| Xian [58]       | RC           | 67             | Mite     | 12                  | TRS, TRMS, VAS, TAS decreased with SCIT/SLIT | SplgG4 increased with SCIT/SLIT |
|                 |              |                |          |                     |                  | IFN-δ increased with SCIT |
|                 |              |                |          |                     |                  | CD4+CD25+Fox p3+ T regs increased with SLIT |
| Keles [85]      | RC           | 60             | Mite     | 18                  | SS, MS, ICS dose, asthma attack frequency decreased with SCIT/SLIT | IL-10, TGF-β, IFN-δ increased with SCIT/SLIT |
|                 |              |                |          |                     |                  | Sp.IgG4 increased with SCIT |
| Antunez [67]    | RC           | 23             | Mite     | 24                  | NE               | Sp.IgG4 increased with SCIT |
| Karakoc-Aydiner [84] | RC        | 48             | Mite     | 36                  | VAS, TRS, TAS, TSS, TMS decreased with SCIT/SLIT | Sp.IgG4 increased with SCIT |
| Yukselen [83]   | RC           | 30             | Mite     | 24                  | TRS, TRS, TRMS, TSS decreased with SCIT/SLIT | IL-10 and Sp.IgG4 increased with SLIT/SCIT |
| Shamji [92]     | RC           | 84             | Grass    | 24                  | At year 1: lower TNSS was detected in the SCIT-treated group. | Higher nasal Sp.IgA and IgE levels in SLIT group subjects. |
|                 |              |                |          |                     | At year 2: TNSS was lower in both SCIT and SLIT groups | Serum Sp.IgG, and IgG4 levels were higher in patients with SCIT |

Abbreviations: Tx: treatment; RC: randomized controlled; NE: not evaluated; TRS: total rhinitis score; RMS: total rhinitis medication score; VAS: visual analogue score; TAS: total asthma score; SS: symptom score; MS: medication score; ICS: inhaled corticosteroid; TSS: total symptom score; TMS: total medication score; TNSS: total nasal symptom score; NP: nasal provocation test.
The isotype-switched antibodies have the potential to inhibit IgE-mediated responses by targeting the IgE epitopes on the allergic antigen and blocking allergen-IgE immune-complexes from binding to IgE receptors [79]. IgG4 is regarded as an efficient blocker of IgE-dependent inflammatory reactions since it has low avidity to allergen and high affinity to inhibitory FcγRIIb receptors [79]. Its induction was suggested as a general maker of successful AIT [80, 81], and in accord, elevated IgG4 levels and decreased IgE/IgG4 ratio were reported after long-term SLIT [49, 50, 59, 67, 75, 76, 78, 82, 83]. However, the relevant literature is not consistent due to studies showing no change in specific IgE, IgG, and IgG4 levels between SLIT-active and SLIT-placebo groups despite the significant decrease in asthmatic symptoms and medication use in the former group [77, 84, 85]. This can be at least partially explained by a mechanism that would generate tolerance against ARD through induction of other specific IgG subclasses including IgG1 and IgG2 [49, 50, 53–55, 57, 59, 62, 63, 65, 67, 75, 76, 78, 82, 86, 87], both of which were also suggested to be with therapeutic importance following AIT [88, 89]. On the other hand, long-term SLIT was also associated with reduced or unchanged serum IgA levels [49, 68] which could be due to enhanced transportation of IgA into the mucosal secretions [75].

When compared with SCIT, SLIT displayed some differences in the efficacy and immune responses that are triggered against ARDs [90, 91] (Table 1). In a study by Schulten et al., patients with ARD exhibited reduced IL-5 levels only following SCIT, but not SLIT [60]. In another report, total rhinitis score was inversely correlated with Treg and IFN-γ levels in SLIT and SCIT, respectively [58]. The SCIT was better in elevating IFN-γ/IL-4 ratio as well as the levels of CD4+CD25+ T-cells and allergen specific IgE and IgG4 antibodies [58, 67, 83–85]. Furthermore, quite recently, both AIT forms were suggested to differ in the predominant antibody class for the induction of tolerance (IgG4 and IgA in SCIT and SLIT, respectively) in patients with ARD [92]. Similar differences were also observed in a mouse model for allergic asthma; SLIT was able to suppress allergen-induced AHR and clinically relevant lung function parameters, but was not able to exert any significant effect on type 2 allergic inflammation which was effectively suppressed by SCIT [86]. In the same study, higher IgG1 and IgG2a levels were reported following SCIT and SLIT, respectively [86]. While these can be suggestive of the possible divergence between the two approaches in the mechanism(s) of action, they can also be due to the other factors such as the higher cumulative dose of allergen and the use of adjuvants in SCIT [93], which are needed to be addressed by future studies for more confirmatory conclusions.
Conclusions
Avoidance to limit the allergen exposure and medications including anti-inflammatory drugs and anti-histamines are among the typical treatment approaches which are in use today against ARD. The AIT provides a unique alternative strategy to both improve the symptom scores and reduce the need for medication [94]. Of the two main forms of AIT, SLIT is regarded as a more practical and safer approach than SCIT since it is a self-administered therapy and exploits the tolerogenic properties of the oral mucosa for the induction of tolerance against allergens.

Previous studies demonstrated the skewing of allergen-specific T-cell differentiation away from the allergic Th2 phenotype to a Th1 and Treg phenotype; and antibody isotype switch from IgE to IgG and IgA in patients with ARD receiving SLIT. The SLIT was also suggested to exert inhibitory activities on innate immune cells including eosinophils, basophils and ICL2 (Figure 1). Nevertheless, the immune-regulatory mechanisms triggered by SLIT still requires more attention in literature to investigate their possible divergence from those triggered by SCIT against ARDs. The clinical application of SLIT can also benefit from the modifications such as using multi-allergens [95], and combination with SCIT [85], and identification of biomarkers associated with SLIT efficacy which would not only help to distinguish non-responders in clinic but also shorten the duration of the treatment.

Acknowledgements
No other persons have made substantial contributions to the manuscript.

Funding
Authors disclose no funding sources.

Conflict of interest
The authors have no conflicts of interest to declare that are relevant to the content of this article.

Author contributions
Concept - UG, NNB; Design – UG; Supervision – NNB; Writing - UG; Critical Reviews - NNB.

Data Availability
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

References
1. Marciniuk DD, Schraufnagel DE, Ferkol T, Fong KM, Joos G, Varela VL, et al. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease. 2nd edn. Sheffield: European Respiratory Society, 2017. Forum of International Respiratory Societies. 2017. Available from https://www.firsnet.org/.
2. Soriano JR, Kendrick PJ, Paulson KR, Gupta V, Abrams EM, Adedoyin RA, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 2020, 8, 585–96.
3. Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1204–22.
4. Laujarinen-Hongisto A, Lyyly A, Hanif T, Dhaygue K, Kankainen M, Renkonen R, et al. Genomics of asthma, allergy and chronic rhinosinusitis: novel concepts and relevance in airway mucosa. Clin Transl Allergy 2020, 10, 45. doi:10.1186/s13601-020-00347-6.
5. Laujarinen-Hongisto A, Toppila-Salmi SK, Luukkainen A, Kern R. Airway epithelial dynamics in allergy and related chronic inflammatory airway diseases. Front Cell Dev Biol 2020, 8, 204. doi:10.3389/fcell.2020.00204.
6. Pfefferle PI, Keber CU, Cohen RM, Garn H. The hygiene hypothesis – learning from but not living in the past. Front Immunol 2021, 12, 635935. doi:10.3389/fimmu.2021.635935.
7. Hesse L, Oude Elberink JNG, van Oosterhout AJM, Nawijn MC. Allergen immunotherapy for allergic airway diseases: use lessons from the past to design a brighter future. Pharmacol Tber 2022, 237, 108115. doi:10.1016/j.pharmthera.2022.108115.
8. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol 2017, 140, 950–8. doi:10.1016/j.jaci.2017.03.050.
9. Global Initiative for Asthma (GINA) Guidelines. Global Strategy for Asthma Management and Prevention. 2019. Available from: https://ginasthma.org/2019/.
10. Del Giudice MM, Licari A, Brambilla L, Tosca MA, Ciprandi G. Allergen immunotherapy in pediatric asthma: a pragmatic point of view. Children 2020, 7, 58. doi:10.3390/children7060058.
11. Hellings PW, Steelant B. Epithelial barriers in allergy and asthma. J Allergy Clin Immunol 2020, 145, 1499–509. doi:10.1016/j.jaci.2020.04.010.
12. Celebi Sözener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in epithelial barrier dysfunction. J Allergy Clin Immunol 2020, 145, 151–28. doi:10.1016/j.jaci.2020.04.024.
13. Maeda K, Caldez MJ, Akira S. Innate immunity in allergy. J Allergy Clin Immunol 2019, 10, 930. doi: 10.3389/fimmu.2019.00930.
14. Liu J, Zhang X, Cheng Y, Cao X. Dendritic cell migration in immune responses: a role in allergic inflammation. Cell Mol Immunol 2020, 18, 2461–71. doi:10.1038/s41423-021-00726-4.
15. Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity 2015, 43, 29–40
16. Helfrich S, Mindt BC, Fritz JH, Duerr CU. Group 2 innate lymphoid cells in respiratory allergic inflammation. Front Immunol 2019, 10, 930. doi: 10.3389/fimmu.2019.00930.
17. Schleimer RP, Berdnikovs S. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. J Allergy Clin Immunol 2017, 139, 1752–61. doi:10.1016/j.jaci.2017.04.010.
18. Nur Husna SM, Tan HTT, Md Shukri N, Mohd Ashari NS, Wong KK. Nasal epithelial barrier integrity and tight junctions disruption in allergic rhinitis: overview and pathogenic insights. Front Immunol 2021, 12, 663626. doi: 10.3389/fimmu.2021.663626.
19. Foster PS, Malathy S, Rosenberg HF, Tay HL, Hogan SP, Collison AM, et al. Modeling TH2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma. Immunol Rev 2017, 278, 20–40. doi:10.1111/imr.12549.
20. Akdis CA, Arkwright PD, Bruggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy 2020, 75, 1582–605.
21. Licari A, Castagnoli R, Denicolò CF, Rossini L, Marsigla A, Marsigla GL. The nose and the lung: united airway disease?. Front Pediatr 2017, 5, 44. doi:10.3389/fped.2017.00044.
23. Hall S, Agrawal DK. Key mediators in the immunopathogenesis of allergic asthma. *Int Immunopharmac Res* 2014, 23, 316–29. doi:10.1016/j.intimp.2014.05.034.

24. Asano K, Ueki S, Tamari M, Imoto Y, Fujieda S, Taniguchi M. Adult-onset cosinophilic airway diseases. *Allergy* 2020, 75, 3087–99.

25. Travers J, Rothenberg ME. Eosinophils in mucosal immune responses. *Mucosal Immunol* 2015, 8, 464–75. doi:10.1038/mi.2015.2.

26. Kucukceker UC, Ozdemir C, Cevhertas L, Ogulur I, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and allergen tolerance. *Allergol Int* 2020, 69, 549–60. doi:10.1016/j.alit.2020.08.002.

27. Field K, Blaiss MS. Sublingual versus subcutaneous immunotherapy for allergic rhinitis: what are the important therapeutic and real-world considerations? *Curr Allergy Asthma Rep* 2020, 20, 45. doi:10.1007/s11882-020-00934-4.

28. Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S, et al. EAACI allergen immunotherapy user’s guide. *Pediatr Allergy Immunol* 2020, 31, 1–101. doi:10.1111/pai.13189.

29. Tsabouri S, Mavroudi A, Fekete G, Guibas GV. Subcutaneous and sublingual immunotherapy in allergic asthma in children. *Front Pediatr* 2017, 5, 82. doi:10.3389/fped.2017.00082.

30. Drazdauskaité G, Layhadi JA, Shamji MH. Mechanisms of allergen immunotherapy in allergic rhinitis. *Curr Allergy Asthma Rep* 2021, 21, 2. doi:10.1007/s11882-020-00977-7.

31. Nagay, M., Shiraishi D, Tanaka Y, Nagasawa Y, Ohwada S, Shimachi H, et al. Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen-presenting cells in mice. *Clin Exp Allergy* 2015, 45, 677–86. doi:10.1111/cea.12329.

32. Miyanaga N, Takagi H, Uto T, Fukaya T, Nasu J, Fukui T, et al. Essential role of submandibular lymph node dendritic cells in protective sublingual immunotherapy against murine allergy. *Commun Biol* 2020, 3, 742. doi:10.1038/s42003-020-01466-3.

33. Saint-Lu N, Tourdot S, Razafindratsita A, Mascarel I, Berjont N, Chabre H, et al. Targeting the allergen to oral dendritic cells with mucosadhesive chitosan particles enhances tolerance induction. *Allergy Eur J Allergy Clin Immunol* 2009, 64, 1003–13.

34. Keshavarz Shahbaz S, Varasteh AR, Koushi K, Kawachi R, et al. Long-term sublingual immunotherapy provides better effects for patients with Japanese cedar pollinosis. *Auris Nasus Larynx* 2021, 48, 646–52. doi:10.1016/j.anl.2021.01.003.

35. Ventura MT, Murgia N, Montuschi F, Gelardi M, Ciabattoni G, Buccionchio R, et al. Exhaled breath condensate, nasal eosinophil cationic protein level and nasal cytology during immunotherapy for cypress allergy. *J Biol Regul Homeost Agents* 2013, 27, 1083–9.

36. Kim JH, Lee JH, Je YM, Lee JH, Park JW, Hur GY, et al. Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites. *Allergy, Asthma Immunol Res* 2018, 10, 675–85. doi:10.4168/aair.2018.10.6.675.

37. Hamada S, Kobayashi Y, Sakamoto D, Shimamura A, Kuroda K, Kawachi R, et al. Long-term sublingual immunotherapy provides better effects for patients with Japanese cedar pollinosis. *Allergy, Asthma Immunol Res* 2018, 10, 675–85. doi:10.4168/aair.2018.10.6.675.

38. Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. *J Allergy Clin Immunol* 2012, 130, 215–24.e7. doi:10.1016/j.jaci.2012.04.021.

39. Zhong H, Fan XL, Yu QN, Qin ZL, Chen D, Xu R, et al. Increased innate type 2 immune response in house dust mite-allergic patients with allergic rhinitis. *Clin Immunol* 2017, 183, 293–9. doi:10.1016/j.clim.2017.09.008.

40. Shamji MH, Layhadi JA, Achikova D, Kouser L, Perera-Webb A, Coutro-Francisco NC, et al. Role of IL-35 in sublingual allergen immunotherapy. *J Allergy Clin Immunol* 2019, 143, 1131–1142. doi:10.1016/j.jaci.2018.06.041.

41. Shimizu K, Koya T, Tsuikoka K, Sagagami T, Hasegawa T, Fukuno T, et al. Effects of sublingual immunotherapy in a murine asthma model sensitized by intranasal administration of house dust mite extracts. *Allergol Int* 2017, 66, 89–96. doi:10.1159/000455102.

42. Pishdadian A, Varasteh A, Ghalamin M, Nasiraei LR, Hosseinpour M, Moghadam M, et al. Lung-derived innate cytokines: new epigenetic targets of allergen-specific sublingual immunotherapy. *Iran J Basic Med Sci* 2016, 19, 64–71.

43. Ghasemi Z, Varasteh AR, Moghadam M, Jalali SA, Anissian A, Sankian M. Sublingual immunotherapy with Sal k1 expressing lactococcus lactis down-regulates Th2 immune responses in Balb/c mice. *Iran J Allergy Asthma Immunol* 2018, 17, 281–90.

44. Ikeda M, Katoh S, Shimizu H, Hasegawa A, Ohashi-Doi K, Oka M. Beneficial effects of Galectin-9 on allergen-specific sublingual immunotherapy in a Dermatophagoides farinae-induced mouse model of chronic asthma. *Allergol Int* 2017, 66, 432–9. doi:10.1159/000446155.

45. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional and immunological effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. *J Allergy Clin Immunol* 2005, 115, 1184–8. doi:10.1016/j.jaci.2005.02.031.

46. La Grutta S, Arena A, D’Anneo WR, Gammeri E, Leonardi S, Trimarchi A, et al. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled trial. *Ear Ann Allergy Clin Immunol* 2007, 39, 40–4.

47. Hamada S, Kobayashi Y, Sakamoto D, Shimamura A, Kuroda K, Kawachi R, et al. Long-term sublingual immunotherapy provides better effects for patients with Japanese cedar pollinosis. *Auris Nasus Larynx* 2021, 48, 646–52. doi:10.1016/j.anl.2021.01.003.

48. Ventura MT, Murgia N, Montuschi F, Gelardi M, Ciabattoni G, Buccionchio R, et al. Exhaled breath condensate, nasal eosinophil cationic protein level and nasal cytology during immunotherapy for cypress allergy. *J Biol Regul Homeost Agents* 2013, 27, 1083–9.

49. Kim JH, Lee JH, Ye YM, Lee JH, Park JW, Hur GY, et al. Efficacy and safety of sublingual immunotherapy in elderly rhinitis patients sensitized to house dust mites. *Allergy, Asthma Immunol Res* 2018, 267
sublingual and subcutaneous immunotherapy in allergic rhinitis with or without asthma. *Int Arch Allergy Immunol* 2020, 181, 71–80. doi:10.1159/000503143.

59. Kinaciyar T, Jahn-Schmid B, Radakovics A, Zwölfer B, Schreiber C, Francis JN, et al. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. *J Allergy Clin Immunol* 2007, 119, 937–43. doi:10.1016/j.jaci.2006.11.010.

60. Schulten V, Tripple V, Asberg K, Backer V, Lund G, Würtzen PA, et al. Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy. *Clin Exp Allergy* 2016, 46, 439–48. doi:10.1111/ceaa.12653.

61. McSorley HJ, O’Gorman MT, Blair N, Sutherland TE, Filbey KJ, Maizels RM. Suppression of type 2 immunity and allergic airway inflammation by secreted products of the helminth Heligmosomoides polygyrus. *Eur J Immunol* 2012, 42, 2667–82. doi:10.1002/eji.201142161.

62. Baron-Bodo V, Horiot S, Lauber A, Chabre H, Drucbert AS, Danze PM, et al. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy. *Clin Exp Allergy* 2013, 43, 1362–73. doi:10.1111/j.1365-2222.2012.12187.x.

63. Pfaar O, Van Twujiwer E, Boot JD, Opstelten DJE, Klimek L, Van Ree R, et al. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. *Allergy* 2016, 99–107. doi:10.1111/all.12760.

64. Dazzo FJ, Carrillo T, Pedemonte C, Plaza Martin AM, Martin Hartado S, Dige E, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergen immunotherapy tablet in adults and children. *J Investig Allergol Clin Immunol* 2014, 24, 154–61.

65. Marcucci F, Sensi I, Incorvaia C, Dell’Albani I, Di Cara G, Frati F. Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapy. *Clin Mol Allergy* 2012, 10, 7. doi:10.1186/1476-7961-10-7.

66. Cortellini G, Spadolini I, Patella V, Fabbri E, Santucci A, Severino M, et al. Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. *Ann Allergy Asthma Immunol* 2010, 105, 382–6. doi:10.1016/j.anai.2010.08.007.

67. Antuñez C, Mayorga C, Corzo JL, Jurado A, Torres MJ. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. *Pediatr Allergy Immunol* 2008, 19, 210–8. doi:10.1111/j.1399-3038.2007.00604.x.

68. Bahcecieler Gazi and Nadir Bahcecieler

69. Bousquet J, Scheinmann P, Guinepin PA, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual–Swallow Immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. *Allergy* 2016, 71, 583–91. doi:10.1111/all.13240.

70. Shamji MH, Valenta R, Jardetzky T, Verhasselt V, Durham SR, Würtzen PA, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. *Allergy* 2020, 76, 3627–41.

71. Weinfield D, Westin U, Hilekst L, Mellqvist UH, Jacobsson I, Cardell LO. A preseason booster prolongs the increase of allergen-specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy. *Allergy, Asthma Clin Exp* 2020, 16, 31. doi:10.1186/s41598-020-00427-z.

72. Zissler UM, Schmidt-Weber CB. Predicting success of allergenspecific immunotherapy. *Front Immunol* 2020, 11, 1826. doi:10.3389/fimmu.2020.01826.

73. Bousquet J, Scheinmann P, Guinepin PA, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual–Swallow Immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. *Allergy* 2016, 71, 583–91. doi:10.1111/all.13240.

74. Kjaer HG, Frølund B, Kristensen MH, Dige E, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergen immunotherapy tablet in adults and children. *J Investig Allergol Clin Immunol* 2014, 24, 154–61.

75. Marcucci F, Sensi I, Incorvaia C, Dell’Albani I, Di Cara G, Frati F. Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapy. *Clin Mol Allergy* 2012, 10, 7. doi:10.1186/1476-7961-10-7.

76. Cortellini G, Spadolini I, Patella V, Fabbri E, Santucci A, Severino M, et al. Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. *Ann Allergy Asthma Immunol* 2010, 105, 382–6. doi:10.1016/j.anai.2010.08.007.

77. Antuñez C, Mayorga C, Corzo JL, Jurado A, Torres MJ. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. *Pediatr Allergy Immunol* 2008, 19, 210–8. doi:10.1111/j.1399-3038.2007.00604.x.

78. Bousquet J, Scheinmann P, Guinepin PA, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual–Swallow Immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. *Allergy* 2016, 71, 583–91. doi:10.1111/all.13240.

79. Shamji MH, Valenta R, Jardetzky T, Verhasselt V, Durham SR, Würtzen PA, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. *Allergy* 2020, 76, 3627–41.

80. Weinfield D, Westin U, Hilekst L, Mellqvist UH, Jacobsson I, Cardell LO. A preseason booster prolongs the increase of allergen-specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy. *Allergy, Asthma Clin Exp* 2020, 16, 31. doi:10.1186/s41598-020-00427-z.

81. Zissler UM, Schmidt-Weber CB. Predicting success of allergen-specific immunotherapy. *Front Immunol* 2020, 11, 1826. doi:10.3389/fimmu.2020.01826.

82. Kjaer HG, Frølund B, Kristensen MH, Dige E, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergen immunotherapy tablet in adults and children: a randomized clinical trial. *J Am Med Assoc* 2016, 315, 1715–25.

83. Bousquet J, Scheinmann P, Guinepin PA, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual–Swallow Immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. *Allergy* 2016, 71, 583–91. doi:10.1111/all.13240.

84. Bousquet J, Scheinmann P, Guinepin PA, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual–Swallow Immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. *Allergy* 2016, 71, 583–91. doi:10.1111/all.13240.

85. Kjaer HG, Frølund B, Kristensen MH, Dige E, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergen immunotherapy tablet in adults and children: a randomized clinical trial. *J Am Med Assoc* 2016, 315, 1715–25.

86. Bousquet J, Scheinmann P, Guinepin PA, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual–Swallow Immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. *Allergy* 2016, 71, 583–91. doi:10.1111/all.13240.

87. Kjaer HG, Frølund B, Kristensen MH, Dige E, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergen immunotherapy tablet in adults and children: a randomized clinical trial. *J Am Med Assoc* 2016, 315, 1715–25.
marker of allergen immunotherapy efficacy. *Allergy Eur J Allergy Clin Immunol* 2021, 77, 1263–73. doi:10.1111/all.15107.

89. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. *J Allergy Clin Immunol* 2005, 116, 608–13. doi:10.1016/j.jaci.2005.06.004.

90. Bahceciler NN, Galip N. Comparing subcutaneous and sublingual immunotherapy: what do we know?. *Curr Opin Allergy Clin Immunol* 2012, 12, 640–7. doi:10.1097/ACI.0b013e328358d5f2.

91. Bahceciler NN, Cobanoglu N. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma. *Immunotherapy* 2011, 3, 747–56. doi:10.2217/imt.11.48.

92. Shamji MH, Larson D, Eifan A, Scadding GW, Qin T, Lawson K, et al. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. *J Allergy Clin Immunol* 2021, 148, 1061–1071.e11. doi:10.1016/j.jaci.2021.03.030.

93. Lawrence MG, Steinke JW, Borish L. Basic science for the clinician: mechanisms of sublingual and subcutaneous immunotherapy. 2016;

94. Nadir Bahceciler N, Galip N, Babayigit A. Steroid sparing effect of sublingual immunotherapy: real life study in mono/polysensitized children with asthma. *Immunotherapy* 2017, 9, 1263–9. doi:10.2217/imt-2017-0110.

95. Bahceciler NN, Galip N, Cobanoglu N. Multiallergen-specific immunotherapy in polysensitized patients: where are we?. *Immunotherapy* 2013, 5, 183–90. doi:10.2217/imt.12.161.